Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma
Omalizumab is approved for treating severe allergic asthma from age 6, but the definition of severe asthma including a systematic assessment to rule out difficult-to-treat asthma has changed since the drug was...
Source: Allergy, Asthma and Clinical Immunology - Category: Allergy & Immunology Authors: Daniel P. Henriksen, Uffe Bodtger, Kirsten Sidenius, Niels Maltbaek, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Ole Norgaard, Louise K. Madsen and Bo L. Chawes Tags: Review Source Type: research